Biotech ETF Strengthens on Optimism Over CRISPR Advancements
March 01, 2019 at 13:00 PM EST
A targeted biotechnology ETF strategy jumped Friday after Editas Medicine (EDIT) announced fourth quarter results, revealing its latest progress toward the commercialization of its EDIT-101 drug candidate and its expansion into other novel CRISPR developments.
